Filing Details
- Accession Number:
- 0001140361-17-045017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-12-05 12:55:42
- Reporting Period:
- 2017-12-01
- Accepted Time:
- 2017-12-05 12:55:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501989 | Cytomx Therapeutics Inc. | CTMX | Pharmaceutical Preparations (2834) | 273521219 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1654058 | A. Sean Mccarthy | C/O Cytomx Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-11-30 | 398 | $12.15 | 4,643 | No | 5 | A | Direct | |
| Common Stock | Acquisiton | 2017-12-01 | 4,100 | $0.95 | 8,743 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-12-01 | 10,240 | $1.13 | 18,983 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-12-01 | 14,340 | $20.60 | 4,643 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2017-12-01 | 4,100 | $0.00 | 4,100 | $0.95 |
| Common Stock | Stock Option (right to buy) | Disposition | 2017-12-01 | 10,240 | $0.00 | 10,240 | $1.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 115,193 | 2023-02-25 | No | 4 | M | Direct | |
| 356,721 | 2021-09-20 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 158,737 | Indirect | See footnote |
Footnotes
- 398 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.42 to $20.78, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
